>AT2G26910.1 |  PDR4 (PLEIOTROPIC DRUG RESISTANCE 4) ATPase coupled to transmembrane movement of substances 
MWNSAENAFSRSTSFKDEIEDEEELRWAALQRLPTYSRIRRGIFRDMVGEPKEIQIGNLE 
ASEQRLLLDRLVNSVENDPEQFFARVRKRFDAVDLKFPKIEVRFQNLMVESFVHVGSRAL 
PTIPNFIINMAEGLLRNIHVIGGKRNKLTILDGISGVIRPSRLTLLLGPPSSGKTTLLLA 
LAGRLGTNLQTSGKITYNGYDLKEIIAPRTSAYVSQQDWHVAEMTVRQTLEFAGRCQGVG 
FKYDMLLELARREKLAGIVPDEDLDIFMKSLALGGMETSLVVEYVMKILGLDTCADTLVG 
DEMIKGISGGQKKRLTTGELLVGPARVLFMDEISNGLDSSTTHQIIMYMRHSTHALEGTT 
VISLLQPSPETYELFDDVILMSEGQIIYQGPRDEVLDFFSSLGFTCPDRKNVADFLQEVT 
SKKDQQQYWSVPFRPYRYVPPGKFAEAFRSYPTGKKLAKKLEVPFDKRFNHSAALSTSQY 
GVKKSELLKINFAWQKQLMKQNAFIYVFKFVQLLLVALITMTVFCRTTMHHNTIDDGNIY 
LGSLYFSMVIILFNGFTEVPMLVAKLPVLYKHRDLHFYPSWAYTLPSWLLSIPTSIIESA 
TWVAVTYYTIGYDPLFSRFLQQFLLYFSLHQMSLGLFRVMGSLGRHMIVANTFGSFAMLV 
VMTLGGFIISRDSIPSWWIWGYWISPLMYAQNAASVNEFLGHNWQKTAGNHTSDSLGLAL 
LKERSLFSGNYWYWIGVAALLGYTVLFNILFTLFLAHLNPWGKFQAVVSREELDEREKKR 
KGDEFVVELREYLQHSGSIHGKYFKNRGMVLPFQPLSLSFSNINYYVDVPLGLKEQGILE 
DRLQLLVNITGAFRPGVLTALVGVSGAGKTTLMDVLAGRKTGGTIEGDVYISGFPKRQET 
FARISGYCEQNDVHSPCLTVVESLLFSACLRLPADIDSETQRAFVHEVMELVELTSLSGA 
LVGLPGVDGLSTEQRKRLTIAVELVANPSIVFMDEPTSGLDARAAAIVMRTVRNIVNTGR 
TIVCTIHQPSIDIFESFDELLFMKRGGELIYAGPLGQKSCELIKYFESIEGVQKIKPGHN 
PAAWMLDVTASTEEHRLGVDFAEIYRNSNLCQRNKELIEVLSKPSNIAKEIEFPTRYSQS 
LYSQFVACLWKQNLSYWRNPQYTAVRFFYTVVISLMLGTICWKFGSKRDTQQQLFNAMGS 
MYAAVLFIGITNATAAQPVVSIERFVSYRERAAGMYSALPFAFAQVFIEFPYVLAQSTIY 
STIFYAMAAFEWSAVKFLWYLFFMYFSIMYFTFYGMMTTAITPNHNVASIIAAPFYMLWN 
LFSGFMIPYKRIPLWWRWYYWANPVAWTLYGLLVSQYGDDERSVKLSDGIHQVMVKQLLE 
DVMGYKHDFLGVSAIMVVAFCVFFSLVFAFAIKAFNFQRR*
>AT3G30842.1 |  PDR10 (PLEIOTROPIC DRUG RESISTANCE 10) ATP binding / ATPase/ nucleoside-triphosphatase/ nucleotide binding 
MAHYRVSSEVENIMNRDRSHRKNEEEDEEEALKLAAMEKLQRLPTYDRARKAVLKGITGG 
FKEIDMKDLGLAERRELFDRVMTMDDEDWHGEYLRRLKSRFDRVSLHLPTIEVRFEDLNV 
TAEAYAGSKTVPTVLNSYVNLLKGIGTKIRVLPDRKKRISILNDVSGIIKPGRLTLLLGP 
PGSGKSTLLKALSGKTETGLRSTGKVTYNGHELHEFVPERTAGYIDQYDVHLPDLTVRET 
LKFSAKCQGVGTGYDMLAELLRREKDLNIKPDPYLDALMKASVIKGHKEYVVTDYVLKVL 
GLEICADTIVGNHMKRGISGGQKKRVTTGEMLVGPVGAFFMDNISDGLDSSTTFQIVKSI 
KQMIHVFDKTALISLLQPPPETFELFDDVIILGEGHIVYQGPREDVLEFFEFMGFKCPER 
KGIADYLQEILSKKDQEQYWANPELPYRYVTAKKFEEGFKIHHFGRAMRSQLATPFDRLK 
NHRAALTRTTYGASKLELLKACLERESILMKRNLRTFVLKSLQLIINAILIGVVFWQQKN 
YPSTVEDGIIYMGAIYLEVQMIVFSGFFELPMTIDKLPVFYKQRHFSFYPSWAFSLPTSI 
ITFPLSFVEVFIVVLITYFTIGYDLTVPSFLKHYLVLALCGQMSYGLFRCIAAVTRNHVV 
SNTMGCLAVMWLMTFSGYVLSRNQVHKWLTWAYWTSPMMYIQTAVSVNEFRSESWKDVIS 
KKPFFKFSTSHFKDIKLNRVVYDFQGLGVAVLKSREYGISKTAVLPDEREEADSNNTTGR 
DYTGTTMERFFDRVVTTRTCNDKKLRIPFKPLYMTFENITYSVDTPKEMKEKGIRENKLV 
LLNGLSGAFRPGVLTALMGVSGAGKTTLMDVLAGRKNTGYIQGEIYVSGFPKKQDSFARV 
SGYCEQSDIHSPLLTVYESLLYSAWLRLPPDIDTHTREVMELIELKALREMLVGYVGISG 
LSTEQRKRMTIAVELVANPSILFMDEPTSGLDARAAAIVMRTVRNTVDTGRTVVCTIHQP 
SIDIFESFDELFLLTRGGEEIYVGPIGHHSSQLIEYFEGIRGVGKIKEGYNPATWALEVT 
TRAQEDVLGVTFAQVYKKSNLYRRNKDLIKELNNIPPHAQDIHFSTKYSQSYLSQFQACL 
WKQHKSYWRNVPYNAVRFSFGAAVGIMYGIIFWSLGKRKGTRQDIFNSVGAMSTVVGFLS 
SQSAATVRPVVIAERTVFYREAGAGMYSALPYAFSQVIIEIPYTMAQACIYGVIVYGMIG 
YEWTASKFFLNIFFTFISILYSIYTGIMVISVSPNQEIASILNGVISTSWNVFSGFTIPR 
PRMHVWLRWFTYVCPGWWGLYGLTIAQYGDVETRLDTGETVVEFMKNYYGYEYNFLWVVS 
LTLIAFSMFFVFIYAFSVKILNFQKR*